ANI PHARMACEUTICALS INC (ANIP) Stock News
NASDAQ:ANIP - Nasdaq - US00182C1036 - Common Stock - Currency: USD
ANIP Latest News, Press Relases and Analysis
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
Mentions: AGEN
Zacks.com featured highlights include ANI Pharmaceuticals, Heritage Insurance, Avista and Exelon
ANI Pharmaceuticals, Heritage Insurance, Avista and Exelon are part of the Zacks Screen of the Week article.
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue
It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Stride, 908 Devices, & Contango are well-poised to gain.
4 Stocks Trading Near 52-Week High With Room to Rise Further
Investors target stocks that have been on a bullish run lately. Stocks like ANIP, HRTG, AVA and EXC are seeing price strength and the momentum is likely to continue.
ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out?
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.
ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings?
Even during a down period for the markets, ANI Pharmaceuticals has gone against the grain, climbing to $68.06. Its shares have yielded a 16.1% return over the last six months, beating the S&P 500 by 23%. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Mentions: TDG
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company...
Jim Cramer Praises Philip Morris International Inc. (PM): “They Have the Best Pricing Power” in a Market Meltdown
We recently published a list of Jim Cramer Reveals Stocks Benefiting From Tariff Selloff & Discusses These 8 Stocks. In this article, we are going to take a look at where Philip Morris International Inc. (NYSE:PM) stands against other stocks that Jim Cramer discusses. In his appearance on CNBC’s Squawk on the Street on Thursday, […]
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil...
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets
PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of...
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®
BAUDETTE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed...
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label
ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic...
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe
PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug...
Why Is ANI Pharmaceuticals (ANIP) Stock Soaring Today
Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 13.4% in the pre-market session after the company reported strong fourth-quarter 2024 results, significantly surpassing analysts' revenue expectations. Revenue surged 45% year-on-year, fueled by continued growth in its Rare Disease segment. Purified Cortrophin Gel led the way with a 42% rise, while the newly added ILUVIEN and YUTIQ products also boosted sales. The company raised its 2025 outlook, now expecting sa
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q4, Stock Soars
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2024, with sales up 44.8% year on year to $190.6 million. The company’s full-year revenue guidance of $766 million at the midpoint came in 5.7% above analysts’ estimates. Its non-GAAP profit of $1.63 per share was 13.6% above analysts’ consensus estimates.
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance
Generated record quarterly net revenues of $190.6 million, representing year-over-year growth of 44.8%Total Rare Disease quarterly net revenue of $87.0...
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March
PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani,...
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company...
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference
PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani,...